BRIEF—Vectorite in-licenses dendritic cell-based vaccine technologies

Taiwan start-up Vectorite Biomedical has in-licensed dendritic cell-based vaccine technologies and natural killer cell technologies from Tokyo, Japan-based biotech Tella to co-develop cancer treatments in Taiwan.

Vectorite will pay Tella $800,000 upfront, and later royalties based on sales.

The deal followed the recently amended policy which allows autologous cell-based immunotherapies to be used on certain cancer patients without going through clinical studies.

The company, which was founded in 2004, develops adoptive cell therapy (ACT) technologies, which are applied in cell therapy technology and cellular-based biologics products development.